Roflumilast Cream 0.05% Draws Attention for Infant Atopic Dermatitis

Roflumilast cream 0.05% is emerging as a potential treatment option for infants with atopic dermatitis, and Arcutis wants dermatologists to know the evidence base is growing.

The story comes via a new interview feature from The Dermatology Digest, in which Arcutis Chief Medical Officer Patrick Burnett discussed the company's PDE4 inhibitor cream and its trajectory in the youngest atopic dermatitis population — infants, a group that has long been underserved by topical therapy.

Why does infant AD matter to prescribers?

Atopic dermatitis affects patients across the age spectrum, but infants remain a difficult cohort. Many approved topicals carry age restrictions that leave caregivers and physicians with narrow choices. Any non-steroidal cream that can demonstrate safety and efficacy in this age band would fill a real gap in pediatric dermatology.

Roflumilast, a phosphodiesterase-4 inhibitor already familiar to dermatologists in other formulations, is being positioned as a steroid-sparing option. The 0.05% concentration now under discussion is specifically the version being studied for this youngest patient group.

The takeaway: a steroid-free topical with infant data would change prescribing conversations in pediatric eczema.

What did Patrick Burnett say?

In the conversation with The Dermatology Digest, Burnett — who serves as Chief Medical Officer at Arcutis, the company developing roflumilast — framed the accumulating evidence in infants as a meaningful step forward for the field. His central claim is that the data supporting roflumilast cream 0.05% in infant atopic dermatitis continues to build.

That is a manufacturer's characterization, and it should be read as such. Still, it signals where the company intends to focus its regulatory and clinical attention next: the youngest end of the AD population, where unmet need is high and approved options are few.

The takeaway: the company's CMO is staking a clear position on infant AD as roflumilast's next frontier.

Where does the evidence go from here?

For dermatologists, the practical questions are straightforward. Will roflumilast cream 0.05% deliver registrational-quality efficacy data in infants? What will the safety profile look like over longer treatment courses in a population with a developing skin barrier? And how will the convenience of a once-daily-style topical fit into caregiver routines?

Those answers will come from continued study and, ultimately, regulatory review. What is clear today is that Arcutis is investing in the infant cohort, and the dermatology community will be watching the maturing dataset closely as it takes shape.